retatrutide fda approval 2025 status october There is a new weight loss shot moving through trials Retatrutide—A Game Changer in Obesity

Ideal Candidate Profiles Adults with confirmed GH deficiency by stimulation testing Patients experiencing age-related GH decline Individuals with mild to moderate metabolic syndrome Contraindications and Precautions Active cancer or history of pituitary tumors Untreated thyroid disorders Pregnancy or breastfeeding Severe kidney or liver impairment Disclose all medical history and medications before starting sermorelin therapy

Weight Health Score: Get a holistic view of how your sleep, activity, and nutrition impact your health

3D, E, Supplemental Fig

cAMP sensor Epac as a determinant of ATP-sensitive potassium channel activity in human pancreatic cells and rat INS-1 cells